An initiative launched by the American Heart Association in September aims to improve in-hospital patient care for patients with HFpEF and HFmrEF.

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a significant advancement in heart failure therapy, combining an ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

San Francisco, CA, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eko, a digital health company applying artificial intelligence (AI) in the fight against heart disease, today announced the U.S. Food and Drug ...

The American College of Cardiology is launching a new program to educate clinicians on the latest advances, medications and interventions emerging in heart failure (HF) management and treatment.

The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...

Among patients with symptomatic chronic heart failure already on guideline-directed medical therapy (GDMT), digitoxin lowered ...

Series A financing will advance the company’s lead candidate for heart failure with reduced ejection fraction (HFrEF) through completion of early clinical development and GMP manufacturing scale-up ...